AI Article Synopsis
- Patients with unresectable colorectal liver metastases often undergo systemic chemotherapy to make their condition operable, but many do not achieve this after first-line treatment.
- Despite limited success with second- and third-line therapies, there’s renewed interest in combining hepatic artery infusion chemotherapy with systemic treatments as a way to improve outcomes.
- Recent studies show promising results for this combined approach, even among patients who are resistant to traditional chemotherapy, leading to wider adoption across North America and beyond.
Article Abstract
Patients with unresectable colorectal liver metastases are commonly treated with systemic chemotherapy to convert their disease to an operable state. Unfortunately, many patients remain unresectable after first-line chemotherapy and resort to second- and third-line regimens with poor results. Liver-directed strategies have historically been used in this setting. There has been a renewed interest in offering hepatic artery infusion chemotherapy combined with systemic chemotherapy to improve resectability or palliate disease. Prospective studies over the past 2 decades have produced encouraging data, even in chemorefractory patients. This therapy has expanded to multiple centers across North America and worldwide with similar results. This review addresses these data, specifically focusing on conversion to resection and palliation of colorectal liver metastases after patients have received multiple lines of systemic chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.surg.2023.04.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!